news

CDMO acquires Meppel facility from Astellas

1
SHARES

Contract development and manufacturing organisation Delpharm has acquired a European pharmaceutical manufacturing facility from Astellas.

CDMO acquires Meppel facility from Astellas

Delpharm has acquired the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The 31,600 square meter facility produces some 40 million finished solid dosage forms each year, including tablets, capsules and pellets.

Meppel will be used to manufacture products for Astellas, according to the terms of the original agreement.  

“We are delighted to further expand our operations in the Netherland with this [third] site,” commented Nicolas Ragot, Managing Director of Delpharm.

The acquisition will strengthen the CDMO’s position in the Netherlands, where it already owns a manufacturing facility in Bladel and an injectable drug development centre in Leiden.

Elsewhere, Delpharm operates pharmaceutical manufacturing facilities at 11 sites in France, two in Italy, two in Canada and one in Poland. The company employs more than 6,500 people, generating revenues of €1.1 billion in 2024.

Delpharm will continue to manufacture the products currently made at the plant in Meppel and will deliver them to Astellas”

Astellas announced its decision to sell the Meppel facility in May 2023. Under the terms of that agreement, Delpharm will continue to manufacture the products currently made at the plant in Meppel and will deliver them to Astellas. The financial terms of the transaction were not disclosed.

“This collaboration between Delpharm and Astellas will allow Astellas to utilise a high-quality and efficient outsourced manufacturing system in Meppel,” the Astellas statement said.  

Share via
Share via